참고문헌
- Agatsuma, T., Ogawa, H., Akasaka, K., Asai, A., Yamashita, Y., Mizukami, T., Akinaga, S. and Saitoh, Y. (2002) Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activities. Bioorg. Med. Chem. 10, 3445-3454. https://doi.org/10.1016/S0968-0896(02)00260-2
- Barker, C. R., Hamlett, J., Pennington, S. R., Burrows, F., Lundgren, K., Lough, R., Watson, A. J. and Jenkins, J. R. (2006) The topoisomerase II-Hsp90 complex: A new chemotherapeutic target? Int. J. Cancer 118, 2685-2693. https://doi.org/10.1002/ijc.21717
- Basarab, G. S., Kern, G. H., McNulty, J., Mueller, J. P., Lawrence, K., Vishwanathan, K., Alm, R. A., Barvian, K., Doig, P., Galullo, V., Gardner, H., Gowravaram, M., Huband, M., Kimzey, A., Morningstar, M., Kutschke, A., Lahiri, S. D., Perros, M., Singh, R., Schuck, V. J., Tommasi, R., Walkup, G. and Newman, J. V. (2015) Responding to the challenge of untreatable gonorrhea: ETX0914, a first-inclass agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci. Rep. 5, 11827. https://doi.org/10.1038/srep11827
-
Baviskar, A. T., Madaan, C., Preet, R., Mohapatra, P., Jain, V., Agarwal, A., Guchhait, S. K., Kundu, C. N., Banerjee, U. C. and Bharatam, P. V. (2011) N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase
$II{\alpha}$ and induce apoptosis in G1/S phase. J. Med. Chem. 54, 5013-5030. https://doi.org/10.1021/jm200235u - Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K. M., Collins, I., Davies, N. G., Drysdale, M. J., Dymock, B., Eccles, S. A., Finch, H., Fink, A., Hayes, A., Howes, R., Hubbard, R. E., James, K., Jordan, A. M., Lockie, A., Martins, V., Massey, A., Matthews, T. P., McDonald, E., Northfield, C. J., Pearl, L. H., Prodromou, C., Ray, S., Raynaud, F. I., Roughley, S. D., Sharp, S. Y., Surgenor, A., Walmsley, D. L., Webb, P., Wood, M., Workman, P. and Wright, L. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J. Med. Chem. 51, 196-218. https://doi.org/10.1021/jm701018h
- Chene, P. (2002) ATPases as drug targets: Learning from their structure. Nat. Rev. Drug Discov. 1, 665-673. https://doi.org/10.1038/nrd894
- Chene, P., Rudloff, J., Schoepfer, J., Furet, P., Meier, P., Qian, Z., Schlaeppi, J. M., Schmitz, R. and Radimerski, T. (2009) Catalytic inhibition of topoisomerase II by a novel rationally designed ATPcompetitive purine analogue. BMC Chem. Biol. 9, 1. https://doi.org/10.1186/1472-6769-9-1
- Chiosis, G., Timaul, M. N., Lucas, B., Munster, P. N., Zheng, F. F., Sepp-Lorenzino, L. and Rosen, N. (2001) A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 8, 289-299. https://doi.org/10.1016/S1074-5521(01)00015-1
- Dutta Gupta, S., Snigdha, D., Mazaira, G. I., Galigniana, M. D., Subrahmanyam, C. V., Gowrishankar, N. L. and Raghavendra, N. M. (2014) Molecular docking study, synthesis and biological evaluation of schiff bases as Hsp90 inhibitors. Biomed. Pharmacother. 68, 369-376. https://doi.org/10.1016/j.biopha.2014.01.003
- Dutta, R. and Inouye, M. (2000) GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25, 24-28. https://doi.org/10.1016/S0968-0004(99)01503-0
- Furet, P., Schoepfer, J., Radimerski, T. and Chene, P. (2009) Discovery of a new class of catalytic topoisomerase II inhibitors targeting the atp-binding site by structure based design. Part I. Bioorg. Med. Chem. Lett. 19, 4014-4017. https://doi.org/10.1016/j.bmcl.2009.06.034
-
Gui, M., Shi, D. K., Huang, M., Zhao, Y., Sun, Q. M., Zhang, J., Chen, Q., Feng, J. M., Liu, C. H., Li, M., Li, Y. X., Geng, M. and Ding, J. (2011) D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase
$II{\alpha}$ . Invest. New Drugs 29, 800-810. https://doi.org/10.1007/s10637-010-9425-3 - Hall, T. A. (1999) BioEdit: A user-friendly biological sequence alignment editor and analysis program for windows 95/98/nt. Nucl. Acids Symp. Ser. 41, 95-98.
- Hu, C. X., Zuo, Z. L., Xiong, B., Ma, J. G., Geng, M. Y., Lin, L. P., Jiang, H. L. and Ding, J. (2006) Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol. Pharmacol. 70, 1593-1601. https://doi.org/10.1124/mol.106.027714
- Huang, H., Chen, Q., Ku, X., Meng, L., Lin, L., Wang, X., Zhu, C., Wang, Y., Chen, Z., Li, M., Jiang, H., Chen, K., Ding, J. and Liu, H. (2010) A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase iialpha catalytic activity. J. Med. Chem. 53, 3048-3064. https://doi.org/10.1021/jm9014394
- Ikuina, Y., Amishiro, N., Miyata, M., Narumi, H., Ogawa, H., Akiyama, T., Shiotsu, Y., Akinaga, S. and Murakata, C. (2003) Synthesis and antitumor activity of novel o-carbamoylmethyloxime derivatives of radicicol. J. Med. Chem. 46, 2534-2541. https://doi.org/10.1021/jm030110r
- Jain, A. N. (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 46, 499-511. https://doi.org/10.1021/jm020406h
- Jensen, L. H., Liang, H., Shoemaker, R., Grauslund, M., Sehested, M. and Hasinoff, B. B. (2006) A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs. Mol. Pharmacol. 70, 1503-1513. https://doi.org/10.1124/mol.106.026856
- Jensen, L. H., Thougaard, A. V., Grauslund, M., Sokilde, B., Carstensen, E. V., Dvinge, H. K., Scudiero, D. A., Jensen, P. B., Shoemaker, R. H. and Sehested, M. (2005) Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res. 65, 7470-7477. https://doi.org/10.1158/0008-5472.CAN-05-0707
- Jez, J. M., Chen, J. C., Rastelli, G., Stroud, R. M. and Santi, D. V. (2003) Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem. Biol. 10, 361-368. https://doi.org/10.1016/S1074-5521(03)00075-9
- Jimenez-Alonso, S., Orellana, H. C., Estevez-Braun, A., Ravelo, A. G., Perez-Sacau, E. and Machin, F. (2008) Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors. J. Med. Chem. 51, 6761-6772. https://doi.org/10.1021/jm800499x
-
Jun, K. Y., Lee, E. Y., Jung, M. J., Lee, O. H., Lee, E. S., Park Choo, H. Y., Na, Y. and Kwon, Y. (2011) Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase
$II{\alpha}$ catalytic inhibitor. Eur. J. Med. Chem. 46, 1964-1971. https://doi.org/10.1016/j.ejmech.2011.01.011 -
Kang, K., Nho, C. W., Kim, N. D., Song, D. G., Park, Y. G., Kim, M., Pan, C. H., Shin, D., Oh, S. H. and Oh, H. S. (2014) Daurinol, a catalytic inhibitor of topoisomerase
$II{\alpha}$ , suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase. Int. J. Oncol. 45, 558-566. https://doi.org/10.3892/ijo.2014.2442 - Kreusch, A., Han, S., Brinker, A., Zhou, V., Choi, H. S., He, Y., Lesley, S. A., Caldwell, J. and Gu, X. J. (2005) Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett. 15, 1475-1478. https://doi.org/10.1016/j.bmcl.2004.12.087
- Kung, P. P., Funk, L., Meng, J., Collins, M., Zhou, J. Z., Johnson, M. C., Ekker, A., Wang, J., Mehta, P., Yin, M. J., Rodgers, C., Davies, J. F., 2nd, Bayman, E., Smeal, T., Maegley, K. A. and Gehring, M. R. (2008) Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone. Bioorg. Med. Chem. Lett. 18, 6273-6278. https://doi.org/10.1016/j.bmcl.2008.09.081
- Li, P. H., Zeng, P., Chen, S. B., Yao, P. F., Mai, Y. W., Tan, J. H., Ou, T. M., Huang, S. L., Li, D., Gu, L. Q. and Huang, Z. S. (2016) Synthesis and mechanism studies of 1,3-benzoazolyl substituted pyrrolo[2,3-b]pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitors. J. Med. Chem. 59, 238-252. https://doi.org/10.1021/acs.jmedchem.5b01284
- Li, Y., Luan, Y., Qi, X., Li, M., Gong, L., Xue, X., Wu, X., Wu, Y., Chen, M., Xing, G., Yao, J. and Ren, J. (2010) Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting atp hydrolysis of topoisomerase II. Toxicol. Sci. 118, 435-443. https://doi.org/10.1093/toxsci/kfq282
- Liang, J., Edelsbrunner, H. and Woodward, C. (1998) Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein Sci. 7, 1884-1897. https://doi.org/10.1002/pro.5560070905
-
Ma, Y., Wang, J. G., Wang, B. and Li, Z. M. (2011) Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic
${\alpha}$ -aminophosphonates that act as novel topoisomerase II inhibitors. J. Mol. Model. 17, 1899-1909. https://doi.org/10.1007/s00894-010-0898-y - Moulin, E., Barluenga, S. and Winssinger, N. (2005a) Concise synthesis of pochonin A, an HSP90 inhibitor. Org. Lett. 7, 5637-5639. https://doi.org/10.1021/ol052263+
- Moulin, E., Zoete, V., Barluenga, S., Karplus, M. and Winssinger, N. (2005b) Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues. J. Am. Chem. Soc. 127, 6999-7004. https://doi.org/10.1021/ja043101w
- Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., Graham, B., McMenamin, R., O'Brien, M. A., Patel, S., Phillips, T. R., Williams, G., Woodhead, A. J. and Woolford, A. J. (2010) Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J. Med. Chem. 53, 5942-5955. https://doi.org/10.1021/jm100059d
- Neckers, L. (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8, S55-S61. https://doi.org/10.1016/S1471-4914(02)02316-X
- Nitiss, J. L. (2009a) Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9, 338-350. https://doi.org/10.1038/nrc2607
- Nitiss, J. L. (2009b) DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 9, 327-337. https://doi.org/10.1038/nrc2608
-
Park, S. E., Chang, I. H., Jun, K. Y., Lee, E., Lee, E. S., Na, Y. and Kwon, Y. (2013) 3-(3-butylamino-2-hydroxy-propoxy)-1-hydroxyxanthen-9-one acts as a topoisomerase
$II{\alpha}$ catalytic inhibitor with low DNA damage. Eur. J. Med. Chem. 69, 139-145. https://doi.org/10.1016/j.ejmech.2013.07.048 - Patel, K., Piagentini, M., Rascher, A., Tian, Z. Q., Buchanan, G. O., Regentin, R., Hu, Z., Hutchinson, C. R. and McDaniel, R. (2004) Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Chem. Biol. 11, 1625-1633. https://doi.org/10.1016/j.chembiol.2004.09.012
- Petrelli, A. and Giordano, S. (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15, 422-432. https://doi.org/10.2174/092986708783503212
-
Pogorelcnik, B., Perdih, A. and Solmajer, T. (2013) Recent advances in the development of catalytic inhibitors of human DNA topoisomerase
$II{\alpha}$ as novel anticancer agents. Curr. Med. Chem. 20, 694-709. https://doi.org/10.2174/092986713804999402 - Putcha, P., Danzer, K. M., Kranich, L. R., Scott, A., Silinski, M., Mabbett, S., Hicks, C. D., Veal, J. M., Steed, P. M., Hyman, B. T. and McLean, P. J. (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 332, 849-857. https://doi.org/10.1124/jpet.109.158436
-
Qin, Y., Meng, L., Hu, C., Duan, W., Zuo, Z., Lin, L., Zhang, X. and Ding, J. (2007) Gambogic acid inhibits the catalytic activity of human topoisomerase
$II{\alpha}$ by binding to its ATPase domain. Mol. Cancer Ther. 6, 2429-2440. https://doi.org/10.1158/1535-7163.MCT-07-0147 - Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W. and Pearl, L. H. (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260-266. https://doi.org/10.1021/jm980403y
- Rowlands, M. G., Newbatt, Y. M., Prodromou, C., Pearl, L. H., Workman, P. and Aherne, W. (2004) High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal. Biochem. 327, 176-183. https://doi.org/10.1016/j.ab.2003.10.038
- Schulte, T. W. and Neckers, L. M. (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 42, 273-279. https://doi.org/10.1007/s002800050817
- Sidera, K. and Patsavoudi, E. (2014) HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat. Anticancer Drug Discov. 9, 1-20.
- Soga, S., Neckers, L. M., Schulte, T. W., Shiotsu, Y., Akasaka, K., Narumi, H., Agatsuma, T., Ikuina, Y., Murakata, C., Tamaoki, T. and Akinaga, S. (1999) KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 59, 2931-2938.
- Soga, S., Sharma, S. V., Shiotsu, Y., Shimizu, M., Tahara, H., Yamaguchi, K., Ikuina, Y., Murakata, C., Tamaoki, T., Kurebayashi, J., Schulte, T. W., Neckers, L. M. and Akinaga, S. (2001) Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother. Pharmacol. 48, 435-445. https://doi.org/10.1007/s002800100373
- Wang, B., Miao, Z. W., Wang, J., Chen, R. Y. and Zhang, X. D. (2008) Synthesis and biological evaluation of novel naphthoquinone fused cyclic aminoalkylphosphonates and aminoalkylphosphonic monoester. Amino Acids 35, 463-468. https://doi.org/10.1007/s00726-007-0570-8
- Wang, P., Leung, C. H., Ma, D. L., Lu, W. and Che, C. M. (2010) Organoplatinum(II) complexes with nucleobase motifs as inhibitors of human topoisomerase II catalytic activity. Chem. Asian J. 5, 2271-2280. https://doi.org/10.1002/asia.201000451
- Wei, H., Ruthenburg, A. J., Bechis, S. K. and Verdine, G. L. (2005) Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase. J. Biol. Chem. 280, 37041-37047. https://doi.org/10.1074/jbc.M506520200
- Xu, X. L., Bao, Q. C., Jia, J. M., Liu, F., Guo, X. K., Zhang, M. Y., Wei, J. L., Lu, M. C., Xu, L. L., Zhang, X. J., You, Q. D. and Sun, H. P. (2016) CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Sci. Rep. 6, 19004. https://doi.org/10.1038/srep19004
- Yang, S. Y., Jia, X. Z., Feng, L. Y., Li, S. Y., An, G. S., Ni, J. H. and Jia, H. T. (2009) Inhibition of topoisomerase ii by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells. Biochem. Pharmacol. 77, 433-443. https://doi.org/10.1016/j.bcp.2008.10.022
- Yang, Z. Q., Geng, X., Solit, D., Pratilas, C. A., Rosen, N. and Danishefsky, S. J. (2004) New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. J. Am. Chem. Soc. 126, 7881-7889. https://doi.org/10.1021/ja0484348
- Yao, Q., Weigel, B. and Kersey, J. (2007) Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin. Cancer Res. 13, 1591-1600. https://doi.org/10.1158/1078-0432.CCR-06-1750
피인용 문헌
- A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity vol.53, pp.51, 2017, https://doi.org/10.1039/C7CC02372C
- Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship vol.19, pp.7, 2016, https://doi.org/10.2174/1871520619666190118120708
- A chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform vol.55, pp.85, 2016, https://doi.org/10.1039/c9cc05524j
- Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets vol.63, pp.3, 2016, https://doi.org/10.1021/acs.jmedchem.9b00726
- The Use of Methods of Computer-Aided Drug Discovery in the Development of Topoisomerase II Inhibitors: Applications and Future Directions vol.60, pp.8, 2016, https://doi.org/10.1021/acs.jcim.0c00325
- Cannabidiol oxidation product HU-331 is a potential anticancer cannabinoid-quinone: a narrative review vol.3, pp.1, 2016, https://doi.org/10.1186/s42238-021-00067-z